USFDA denies approval to SPARC’s epilepsy drug
In a presentation this June, SPARC had said that the market for the drug in the USA is at 720 million units and is growing at 5 year compounded annual growth rate (CAGR) of 9 per cent. It had forecast that opportunity exists to market Elepsia XR at significant premium to generics.
Posted On Sep 30 2015